NIFTY 50

Launch of Trastuzumab in US market offers a sizeable opportunity for Biocon & Mylan, says Kiran Mazumdar Shaw

Updated : December 03, 2019 09:59 AM IST

We do have a growing portfolio of biosimilar antibodies for cancer, said Kiran Mazumdar Shaw, CMD, Biocon.
At the moment very much on track to achieve sales target of $ 1 billion for biosimilars  by FY22, said Kiran Mazumdar Shaw.
primo org
Have you signed up for Primo, our daily newsletter?
It has all the stories and data on the market, business, economy and tech that you need to know.
cnbc two logos
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more

You May Also Like

Live TV